JPWO2021154839A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021154839A5 JPWO2021154839A5 JP2022546393A JP2022546393A JPWO2021154839A5 JP WO2021154839 A5 JPWO2021154839 A5 JP WO2021154839A5 JP 2022546393 A JP2022546393 A JP 2022546393A JP 2022546393 A JP2022546393 A JP 2022546393A JP WO2021154839 A5 JPWO2021154839 A5 JP WO2021154839A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- vector
- multispecific antibody
- composition
- immune cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 102
- 239000013598 vector Substances 0.000 claims description 83
- 210000002865 immune cell Anatomy 0.000 claims description 58
- 239000013603 viral vector Substances 0.000 claims description 50
- 239000000427 antigen Substances 0.000 claims description 36
- 108091007433 antigens Proteins 0.000 claims description 36
- 102000036639 antigens Human genes 0.000 claims description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- 102000040430 polynucleotide Human genes 0.000 claims description 23
- 108091033319 polynucleotide Proteins 0.000 claims description 23
- 239000002157 polynucleotide Substances 0.000 claims description 23
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 22
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 22
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 20
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 18
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 18
- 230000026683 transduction Effects 0.000 claims description 18
- 238000010361 transduction Methods 0.000 claims description 18
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 16
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 16
- 102000005962 receptors Human genes 0.000 claims description 16
- 108020003175 receptors Proteins 0.000 claims description 16
- 108700019146 Transgenes Proteins 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 14
- 208000035475 disorder Diseases 0.000 claims description 14
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 12
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 12
- 108010057085 cytokine receptors Proteins 0.000 claims description 12
- 102000003675 cytokine receptors Human genes 0.000 claims description 12
- 239000003446 ligand Substances 0.000 claims description 12
- 230000002463 transducing effect Effects 0.000 claims description 12
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 10
- 241000501789 Cocal virus Species 0.000 claims description 10
- 230000006044 T cell activation Effects 0.000 claims description 8
- 238000001727 in vivo Methods 0.000 claims description 8
- 230000009870 specific binding Effects 0.000 claims description 8
- 230000000139 costimulatory effect Effects 0.000 claims description 7
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 6
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 6
- 229960003008 blinatumomab Drugs 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 210000001165 lymph node Anatomy 0.000 claims description 6
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 5
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 4
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 4
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 4
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 4
- 102100038078 CD276 antigen Human genes 0.000 claims description 4
- 101710185679 CD276 antigen Proteins 0.000 claims description 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 4
- 102000000844 Cell Surface Receptors Human genes 0.000 claims description 4
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 101150029707 ERBB2 gene Proteins 0.000 claims description 4
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 claims description 4
- 101710091045 Envelope protein Proteins 0.000 claims description 4
- 108010055196 EphA2 Receptor Proteins 0.000 claims description 4
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims description 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 4
- 108090000288 Glycoproteins Proteins 0.000 claims description 4
- 102000003886 Glycoproteins Human genes 0.000 claims description 4
- 206010066476 Haematological malignancy Diseases 0.000 claims description 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 4
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 4
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims description 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 4
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 4
- 101000829725 Homo sapiens Phospholipid hydroperoxide glutathione peroxidase Proteins 0.000 claims description 4
- 101001056234 Homo sapiens Sperm mitochondrial-associated cysteine-rich protein Proteins 0.000 claims description 4
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 4
- 241000526636 Nipah henipavirus Species 0.000 claims description 4
- 101710188315 Protein X Proteins 0.000 claims description 4
- 102100026503 Sperm mitochondrial-associated cysteine-rich protein Human genes 0.000 claims description 4
- 108091008874 T cell receptors Proteins 0.000 claims description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 230000003211 malignant effect Effects 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 230000002297 mitogenic effect Effects 0.000 claims description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 4
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 4
- 230000000149 penetrating effect Effects 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 2
- 108010037897 DC-specific ICAM-3 grabbing nonintegrin Proteins 0.000 claims description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 2
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 2
- 102100022297 Integrin alpha-X Human genes 0.000 claims description 2
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- 210000000066 myeloid cell Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 31
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025175399A JP2026016490A (ja) | 2020-01-30 | 2025-10-17 | 二特異性形質導入エンハンサー |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062968028P | 2020-01-30 | 2020-01-30 | |
| US62/968,028 | 2020-01-30 | ||
| PCT/US2021/015267 WO2021154839A1 (en) | 2020-01-30 | 2021-01-27 | Bispecific transduction enhancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025175399A Division JP2026016490A (ja) | 2020-01-30 | 2025-10-17 | 二特異性形質導入エンハンサー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023512071A JP2023512071A (ja) | 2023-03-23 |
| JP2023512071A5 JP2023512071A5 (https=) | 2024-02-02 |
| JPWO2021154839A5 true JPWO2021154839A5 (https=) | 2024-02-02 |
Family
ID=74673365
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022546393A Pending JP2023512071A (ja) | 2020-01-30 | 2021-01-27 | 二特異性形質導入エンハンサー |
| JP2025175399A Pending JP2026016490A (ja) | 2020-01-30 | 2025-10-17 | 二特異性形質導入エンハンサー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025175399A Pending JP2026016490A (ja) | 2020-01-30 | 2025-10-17 | 二特異性形質導入エンハンサー |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230348624A1 (https=) |
| EP (1) | EP4096707A1 (https=) |
| JP (2) | JP2023512071A (https=) |
| KR (1) | KR20220144377A (https=) |
| CN (1) | CN115697388A (https=) |
| AU (1) | AU2021213735A1 (https=) |
| CA (1) | CA3165713A1 (https=) |
| IL (1) | IL295129A (https=) |
| WO (1) | WO2021154839A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための組成物および方法 |
| JP7549303B2 (ja) | 2018-01-22 | 2024-09-11 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞の使用方法 |
| CN112105382A (zh) | 2018-02-23 | 2020-12-18 | 恩多塞特公司 | 用于car t细胞疗法的顺序方法 |
| US20260021206A1 (en) * | 2022-07-25 | 2026-01-22 | Vironexis Biotherapeutics Inc. | Adeno-associated virus vectors and methods of their use for reducing the risk of, treating, and preventing metastasis |
| WO2024026505A2 (en) * | 2022-07-29 | 2024-02-01 | Amit Patel | Disruption of telocyte activity |
| WO2024148216A2 (en) * | 2023-01-05 | 2024-07-11 | Neximmune, Inc. | Combination therapy with t cell engager |
| KR20260005358A (ko) | 2023-04-27 | 2026-01-09 | 밀테니 비오텍 비.브이. & 씨오. 케이지 | 항-cd3 디스플레이를 갖는 슈도타이핑된 레트로바이러스 벡터 입자 |
| WO2025078492A1 (en) | 2023-10-13 | 2025-04-17 | Miltenyi Biotec B.V. & Co. KG | Cd3-targeted nipah-pseudotyped lentiviral vector particles |
| WO2025128615A1 (en) * | 2023-12-12 | 2025-06-19 | Seagen Inc. | Multispecific egfr antibodies and use in the treatment of cancer |
| WO2026068705A1 (en) * | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| DE69434860T2 (de) | 1993-02-22 | 2007-03-15 | The Rockefeller University | Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6004797A (en) | 1995-11-09 | 1999-12-21 | Avigen, Inc. | Adenovirus helper-free recombinant AAV Virion production |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| CZ302070B6 (cs) | 1998-04-21 | 2010-09-29 | Micromet Ag | Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| NZ532635A (en) | 2001-11-13 | 2007-05-31 | Univ Pennsylvania | A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method |
| AU2003274397A1 (en) | 2002-06-05 | 2003-12-22 | University Of Florida | Production of pseudotyped recombinant aav virions |
| CN100376599C (zh) * | 2004-04-01 | 2008-03-26 | 北京安波特基因工程技术有限公司 | 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体 |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| US8871912B2 (en) | 2006-03-24 | 2014-10-28 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| US7588772B2 (en) | 2006-03-30 | 2009-09-15 | Board Of Trustees Of The Leland Stamford Junior University | AAV capsid library and AAV capsid proteins |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| JP2011507519A (ja) | 2007-12-19 | 2011-03-10 | セントコア・オーソ・バイオテツク・インコーポレーテツド | ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法 |
| BRPI0910482A2 (pt) | 2008-04-29 | 2019-09-24 | Abbott Lab | imunoglobinas de domínio variável duplo e usos das mesmas |
| JP2012525149A (ja) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヘテロ多量体分子を作製するための方法 |
| DK2560993T3 (da) | 2010-04-20 | 2024-10-14 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| EP2420253A1 (en) | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Engineering multifunctional and multivalent molecules with collagen XV trimerization domain |
| PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| US10344050B2 (en) | 2011-10-27 | 2019-07-09 | Genmab A/S | Production of heterodimeric proteins |
| CA2854233C (en) | 2011-11-04 | 2020-05-12 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| US9434928B2 (en) | 2011-11-23 | 2016-09-06 | Nationwide Children's Hospital, Inc. | Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides |
| LT2794905T (lt) | 2011-12-20 | 2020-07-10 | Medimmune, Llc | Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams |
| WO2013148327A1 (en) | 2012-03-26 | 2013-10-03 | The Regents Of The University Of California | Nipah virus envelope psuedotyped lentiviruses and methods of their use |
| SI2838917T1 (sl) | 2012-04-20 | 2019-11-29 | Merus Nv | Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul |
| EP3447072A3 (en) * | 2013-03-05 | 2019-05-22 | Baylor College of Medicine | Engager cells comprising cd3 scfv and an antigen recognition domain that binds a tumor antigen for immunotherapy |
| WO2015017214A1 (en) | 2013-07-29 | 2015-02-05 | Bluebird Bio, Inc. | Multipartite signaling proteins and uses thereof |
| NZ725201A (en) * | 2014-04-25 | 2018-05-25 | Bluebird Bio Inc | Improved methods for manufacturing adoptive cell therapies |
| US10781459B2 (en) | 2014-06-20 | 2020-09-22 | University Of Florida Research Foundation, Incorporated | Methods of packaging multiple adeno-associated virus vectors |
| GB201503500D0 (en) | 2015-03-02 | 2015-04-15 | Ucl Business Plc | Cell |
| EP3356407B1 (en) * | 2015-10-02 | 2021-11-03 | F. Hoffmann-La Roche AG | Bispecific anti-cd19xcd3 t cell activating antigen binding molecules |
| GB201602974D0 (en) * | 2016-02-19 | 2016-04-06 | Clube Jasper R | Engineered cells & methods (1) |
| IL261713B2 (en) | 2016-03-19 | 2023-09-01 | F1 Oncology Inc | Methods and preparations for the transfer of lymphocytes and their regulated expansion |
| WO2017172981A2 (en) * | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| CN109476749A (zh) * | 2016-06-30 | 2019-03-15 | 豪夫迈·罗氏有限公司 | 改良的过继性t细胞疗法 |
| ES2897217T3 (es) | 2016-09-30 | 2022-02-28 | Hoffmann La Roche | Anticuerpos biespecíficos frente a p95HER2 |
| AU2017370644A1 (en) * | 2016-12-05 | 2019-06-13 | Juno Therapeutics, Inc. | Production of engineered cells for adoptive cell therapy |
| JP7206214B2 (ja) | 2016-12-13 | 2023-01-17 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | インビトロ及びインビボで操作された細胞において発現された化学誘導シグナル伝達複合体の外因性薬物活性化の方法 |
| CN110612119B (zh) | 2017-02-07 | 2024-10-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
| AU2018337142B2 (en) | 2017-09-22 | 2025-07-03 | Wuxi Biologics Ireland Limited. | Novel bispecific CD3/CD19 polypeptide complexes |
| SG11202007426XA (en) | 2018-02-06 | 2020-09-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| CN112262214A (zh) * | 2018-04-12 | 2021-01-22 | 优莫佳生物制药股份有限公司 | 病毒载体及包装细胞系 |
-
2021
- 2021-01-27 US US17/796,523 patent/US20230348624A1/en active Pending
- 2021-01-27 IL IL295129A patent/IL295129A/en unknown
- 2021-01-27 CN CN202180023572.XA patent/CN115697388A/zh active Pending
- 2021-01-27 WO PCT/US2021/015267 patent/WO2021154839A1/en not_active Ceased
- 2021-01-27 CA CA3165713A patent/CA3165713A1/en active Pending
- 2021-01-27 KR KR1020227030104A patent/KR20220144377A/ko active Pending
- 2021-01-27 EP EP21707497.0A patent/EP4096707A1/en active Pending
- 2021-01-27 JP JP2022546393A patent/JP2023512071A/ja active Pending
- 2021-01-27 AU AU2021213735A patent/AU2021213735A1/en active Pending
-
2025
- 2025-10-17 JP JP2025175399A patent/JP2026016490A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yan et al. | Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment | |
| Fabian et al. | The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy | |
| US12448445B2 (en) | Transgene genetic tags and methods of use | |
| JP7599205B2 (ja) | 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化 | |
| JP6997744B2 (ja) | 細胞免疫療法のための方法および組成物 | |
| US20220249568A1 (en) | Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof | |
| Gargett et al. | The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells | |
| CN113227379A (zh) | 多功能多靶向嵌合抗原受体（car）系统及其使用方法 | |
| JPWO2021154839A5 (https=) | ||
| JPWO2022164935A5 (https=) | ||
| WO2020108642A1 (en) | Cd19-and cd30-based combined car-t immunotherapy | |
| Li et al. | Nanobodies and their derivatives: pioneering the future of cancer immunotherapy | |
| Guo et al. | Humanized CD30-targeted chimeric antigen receptor t cells exhibit potent preclinical activity against Hodgkin’s lymphoma cells | |
| WO2021208750A1 (zh) | 靶向cd22的嵌合抗原受体及其制法和应用 | |
| JPWO2023115033A5 (https=) | ||
| RU2822461C1 (ru) | Трансгенные генетические метки и способы применения | |
| JP2025538424A (ja) | 併用療法の投与レジメン | |
| JPWO2019199165A5 (https=) | ||
| NZ745376B2 (en) | Method and compositions for cellular immunotherapy | |
| HK1233273B (en) | Transgene genetic tags and methods of use |